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Abstract
Background: Macrophage inhibitory cytokine-1 (MIC-1) is a key inducer of cancer-related anorexia and weight loss. 
However, its possible role in the etiopathogenesis of nutritional disorders of other etiology such as anorexia nervosa 
(AN) is currently unknown.
Methods: We measured fasting serum concentrations of MIC-1 in patients with AN before and after 2-month 
nutritional treatment and explored its relationship with nutritional status, metabolic and biochemical parameters. 
Sixteen previously untreated women with AN and twenty-five normal-weight age-matched control women 
participated in the study. We measured serum concentrations of MIC-1 and leptin by ELISA, free fatty acids by 
enzymatic colorimetric assay, and biochemical parameters by standard laboratory methods; determined resting 
energy expenditure by indirect calorimetry; and assessed bone mineral density and body fat content by dual-energy X-
ray absorptiometry. ANOVA, unpaired t-test or Mann-Whitney test were used for groups comparison as appropriate. 
The comparisons of serum MIC-1 levels and other studied parameters in patients with AN before and after partial 
realimentation were assessed by paired t-test or Wilcoxon Signed Rank Test as appropriate.
Results: At baseline, fasting serum MIC-1 concentrations were significantly higher in patients with AN relative to 
controls. Partial realimentation significantly reduced serum MIC-1 concentrations in patients with AN but it still 
remained significantly higher compared to control group. In AN group, serum MIC-1 was inversely related to Buzby 
nutritional risk index, serum insulin-like growth factor-1, serum glucose, serum total protein, serum albumin, and 
lumbar bone mineral density and it significantly positively correlated with the duration of AN and age.
Conclusions: MIC-1 concentrations in AN patients are significantly higher relative to healthy women. Partial 
realimentation significantly decreased MIC-1 concentration in AN group. Clinical significance of these findings needs to 
be further clarified.
Background
Anorexia Nervosa (AN) represents a bordering example
of psychosomatic-based malnutrition induced by chroni-
cally decreased food intake caused by inappropriate fear
of obesity and distorted body image [1-4]. The exact etio-
pathogenesis of AN is still not completely understood.
Although alterations in circulating levels of many appe-
tite-regulating hormones, including leptin and ghrelin, in
concert with many abnormalities in the metabolism of
adipose and other tissues have been previously docu-
mented in patients with AN [5-13] most of these changes
appear rather secondary to compensate for chronically
decreased food intake and malnutrition. None of these
factors can explain the anorectic behavior and prolonged
tendency towards weight loss of these patients. In fact,
the factors contributing to the chronic course of AN are
mostly unknown.
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Macrophage inhibitory cytokine-1 (MIC-1) is a mem-
ber of the transforming growth factor-β superfamily [14].
It is strongly expressed in activated macrophages (14),
adipocytes [15], placenta and prostate, and to lesser
extent in the liver, kidney and brain [16,17]. Significant
amounts of MIC-1 are released into the circulation
[14,18,19] suggesting that it can also act as an endocrine
factor [20].
MIC-1 is involved in the control of multiple cellular
processes, being markedly increased in patients with
chronic inflammatory states such as rheumatoid arthritis
[21] and overexpressed by many types of malignant
tumors [22-26]. MIC-1 was also identified as a predictor
of cardiovascular events in a cohort of previously healthy
women [27], as a new marker predicting death and heart
failure in post-myocardial infarction patients [28], and as
an early mediator of the injury response in kidney and
lung [29].
Recently, a key role of increased MIC-1 concentrations
in the induction of cancer-related anorexia and weight
loss in prostate tumor-bearing mice and in humans with
advanced prostate cancer was described [30]. In the
brain, MIC-1 decreased food intake through modulation
of neuropeptide Y and proopiomelanocortin levels in
nucleus arcuatus [30]. Administration of MIC-1 antibody
to tumor-bearing mice rapidly reversed the weight loss,
w h e r e a s  M I C - 1  a d m i n i s t r a t i o n  t o  n o r m a l  m i c e  o r  i t s
transgenic overexpression induced hypophagia and
decreased body weight [30]. Additionally, MIC-1 gene
expression was recently identified in human subcutane-
ous and visceral fat and it was inversely related to body
mass index and body fat mass [15].
To our best knowledge MIC-1 has not been previously
studied in patients with AN. Chronic malnutrition in
patients with AN shares some common hormonal and
metabolic features with cancer anorexia [31]. Therefore,
we hypothesized that elevated serum levels of MIC-1 may
contribute to reduced appetite, weight loss or possibly
other metabolic and nutritional disturbances in patients
with AN. To this end, we measured fasting serum levels
o f  MIC -1 in pa ti e n ts  wi t h  AN a nd in heal t h y  norm a l-
weight women and studied its relationship to clinical
characteristics, body composition, bone mineral density
and various hormonal and metabolic parameters. Fur-
thermore, we studied the effect of partial realimentation
of patients with AN on serum MIC-1 concentrations and
its relationship to above described clinical characteristics.
Methods
Study subjects
Sixteen previously untreated female patients with AN
(age: 24.9 ± 1.34 years; body mass index (BMI): 15.7 ±
0.30 kg/m2; body fat content (DEXA): 13.9 ± 1.44%) and
twenty-five age- and sex-matched healthy controls (age:
22.9 ± 0.50 years; BMI: 21.8 ± 0.38 kg/m2; body fat con-
tent (DEXA): 26.4 ± 1.79%) were included in the study.
The diagnosis of eating disorder was based on Diagnostic
Statistical Manual IV diagnostic system (DSM-IV). A
clinical evaluation of the patients was performed by an
experienced psychiatrist. The Structured Clinical Inter-
view MINI 5.0 was used for diagnostic assessment of the
patients. None of the studied subjects suffered from dia-
betes mellitus, thyroid disorder and/or acute infectious
disease. None of the studied subjects had malignant
tumor. All women included in the study had no allergies.
Healthy control women had been free of any medication
for at least three months prior to the study and had no
history of obesity or malnutrition, hypertension, gastro-
intestinal disease, eating disorder or other psychiatric dis-
order. Blood tests confirmed normal blood count, liver
and renal functions. All healthy women had regular men-
strual cycle. The baseline examination of the patients was
performed before the start of any treatment. At that time
all patients were free of any medication affecting food
intake and/or appetite.
Written informed consent was provided by all partici-
pants before being enrolled in the study. The study was
approved by the Human Ethical Review Committee, First
Faculty of Medicine and General University Hospital,
Prague, Czech Republic, and was performed in accor-
dance with the guidelines proposed in the Declaration of
Helsinki.
Anthropometric examination and blood sampling
All patients with AN were examined twice; at a basal state
before the beginning of any treatment and after two
months of partial realimentation while normal-weight
healthy women were examined only once. All subjects
were measured and weighted and BMI was calculated.
Body fat content was estimated by bioimpedance analysis
(Bodystat 1500, Bodystat Ltd., UK) and by dual energy X-
ray absorptiometry (DEXA). Bone mineral density was
also estimated by DEXA on QDR 4500A bone densitome-
ter (Hologic, Waltham, MA, USA). Resting energy expen-
diture was determined by indirect calorimetry (Vmax
ENCORE ViasysTH  HEALTHCARE, SensorMedics BV,
Netherlands). Blood samples for MIC-1, and biochemical
parameters measurements were withdrawn between 0700
and 0800 h after 12 h of overnight fasting. Serum was
separated by centrifugation and stored at -80°C until
being assayed.
Nutritional risk index by Buzby (NRI) was calculated
according the following formula: NRI = 1.519 + albumin
(g/l) + 0.417 * actual body weight/ideal body weight * 100.
Ideal body weight was calculated as (0.593*body height) -
38.6. Strong malnutrition is defined by NRI < 83.5 [32].Dostálová et al. Nutrition & Metabolism 2010, 7:34
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Hormonal and biochemical assays
Serum MIC-1 concentrations were measured by a com-
mercial ELISA kit (BioVendor, Brno, Czech Republic).
Sensitivity was 10 pg/ml and the intra- and inter-assay
variability was 3.7% and < 10%. Serum leptin concentra-
tions were measured by commercial ELISA kit (BioVen-
dor, Brno, Czech Republic). Sensitivity was 0.12 ng/ml
and the intra- and inter-assay variability was 1.7 and 8.0%,
respectively. Serum concentrations of insulin-like growth
factor-1 (IGF-1) were measured by commercial IRMA kit
(Immunotech, Prague, Czech Republic). Sensitivity was 2
ng/ml, and the intra- and inter-assay variability was 6.3
and 6.8%, respectively. Serum levels of free fatty acids
were measured by enzymatic colorimetric assay (Roche,
Basel, Switzerland). Serum biochemical parameters (glu-
cose, total and HDL-cholesterol, triglycerides and albu-
min) were measured by standard laboratory methods on
Modular SWA analyzer (Roche Diagnostics, GmbH,
Mannheim, Germany), the value of LDL-cholesterol was
calculated by Friedewald formula.
Statistical analysis
The statistical analysis was performed on SigmaStat soft-
ware (Jandel Scientific, San Rafael, CA). Results are
expressed as mean ± S.E.M. ANOVA, unpaired t-test or
Mann-Whitney test were used for groups comparison as
appropriate. The comparisons of serum MIC-1 levels and
other studied parameters in patients with AN before and
after partial realimentation were assessed by paired t-test
or Wilcoxon Signed Rank T est as appropriate. The uni-
variate correlations between MIC-1 and other parame-
ters were estimated by Spearman Correlation Test.
Multiple regression analysis was used to show the inde-
pendent relationship of other parameters with MIC-1. A
p value < 0.05 denoted statistical significance.
Results
Anthropometric, hormonal and biochemical characteristics 
of the study subjects
The study groups were age-matched. Patients with AN
had severely decreased BMI and body fat content (Table
1). At baseline, patients with AN had significantly
decreased lean body mass and daily resting energy expen-
d i t u r e  a s  c o m p a r e d  w i t h  c o n t r o l  g r o u p .  F a s t i n g  s e ru m
concentrations of leptin, glucose, free fatty acids, and
total serum protein were significantly reduced in AN
group as compared with C group. Fasting LDL choles-
terol levels in untreated AN patients did not significantly
differ from C group.
Fasting serum HDL-cholesterol, total cholesterol and
albumin concentrations did not significantly differ
between the groups. At baseline, lumbar, proximal femur
and total bone mineral density were significantly reduced
in AN group relative to C group (Table 1).
The influence of partial realimentation on anthropo-
metric, hormonal, and biochemical characteristics of
patients with AN is summarized in Table 1. Patients with
AN significantly gained weight and body fat content dur-
ing realimentation. Fasting serum leptin, total serum cho-
lesterol, glucose, total protein, albumin, LDL-cholesterol
concentrations and daily resting energy expenditure sig-
nificantly increased in patients with AN after partial
refeeding as compared with pre-treatment values. Post-
treatment fasting serum HDL-cholesterol concentrations
were not significantly different as compared with its pre-
treatment levels in AN. Post-treatment concentrations of
total cholesterol and LDL-cholesterol were significantly
increased in patients with AN as compared with controls
(Table 1).
Serum levels of MIC-1 in AN and normal-weight women 
and its changes after two-month realimentation
At baseline, fasting serum MIC-1 concentrations were
significantly higher in patients with AN relative to control
group of healthy normal-weight women (Figure 1). Partial
realimentation significantly reduced serum MIC-1 con-
centrations in patients with AN but it still remained sig-
nificantly higher compared to controls (Figure 1).
Relationship of MIC-1 with other studied parameters
The relationship of serum MIC-1 levels with other
parameters was assessed in a combined population of
both groups and separately in patients with AN (Tables 2
and 3). In a combined population (Table 2), serum pre-
treatment MIC-1 concentrations were correlated with
other pre-treatment parameters by Spearman correlation
test. The correlations were normalized for BMI. In a com-
bined group of AN and controls pre-treatment MIC-1
positively correlated with age and serum total cholesterol,
and was inversely related to BMI, lean body mass, serum
glucose, serum albumin, serum leptin, lumbar bone min-
eral density and resting energy expenditure (Table 2).
In patients with AN, univariate correlations were calcu-
lated by Spearman correlation test for pre-treatment
MIC-1 levels with other pre- and post-treatment parame-
ters (Table 3) and post-treatment MIC-1 levels with other
pre- and post-treatment parameters (Table 3), respec-
tively. Both pre- and post-treatment serum MIC-1 levels
were inversely related to post-treatment Buzby nutri-
tional risk index, pre-treatment serum insulin-like
growth factor concentrations, post-treatment total pro-
tein and post-treatment albumin levels. Both pre- and
post-treatment MIC-1 levels positively correlated with
age. Post-treatment serum MIC-1 levels significantly
inversely correlated with post-treatment serum glucose
and pre-treatment lumbar bone mineral density and were
significantly positively associated with the duration of ill-
ness in patients with AN (T able 3). In both groups, weDostálová et al. Nutrition & Metabolism 2010, 7:34
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failed to find any significant relationship of MIC-1 with
body fat content, serum thyroid hormones (fT3, fT4,
TSH), serum free fatty acids, and liver enzymes (aspartate
aminotransferase, alanine aminotransferase).
In patients with AN, delta MIC-1 during treatment sig-
nificantly inversely correlated with delta LBM (r = - 0.70,
p = 0.002) during treatment.
Multiple regression analysis was performed in com-
bined population with pre-treatment MIC-1 levels as
dependent and pre-treatment BMI, lean body mass, glu-
cose, cholesterol, albumin, lumbar bone mineral density,
leptin, resting energy expenditure and age as independent
variables. None of the factors included was identified as
statistically significant independent predictor of pre-
treatment MIC-1 concentrations.
Multiple regression analyses were also performed sepa-
rately in anorexia nervosa group with pre-treatment
MIC-1 and post-treatment MIC-1 levels as dependent
parameters, respectively. First multiple regression analy-
sis was performed with pre-treatment MIC-1 levels as
dependent and pre- and post-treatment Buzby nutri-
tional index, pre-treatment IGF-1, lumbar bone mineral
density, age, duration of illness and post-treatment glu-
cose, total protein and albumin as independent variables.
Similarly as in the combined group of AN and control
subjects none of the factors included was identified as
statistically significant independent predictor of pre-
treatment MIC-1 concentrations.
Another multiple regression analysis was performed for
post-treatment MIC-levels as dependent and pre- and
post-treatment Buzby nutritional index, pre-treatment
Table 1: Characteristics of the study groups.
Controls
(n = 25)
AN pre-treatment
(n = 16)
AN post-treatment
(n = 16)
Age (years) 22.9 ± 0.50 24.9 ± 1.34 24.9 ± 1.34
Body mass index (kg/m2) 21.8 ± 0.38 15.7 ± 0.30* 17.5 ± 0.23*+
Body fat content (bodystat) 
(%)
21.9 ± 1.21 9.3 ± 1.65* 12.8 ± 1.38*+
Body fat content (DEXA) (%) 26.4 ± 1.79 13.9 ± 1.44* 18.0 ± 1.38*+
Lean body mass (kg) 52.5 ± 2.03 38.9 ± 1.3* 41.3 ± 0.96*
Resting energy expenditure 
(kcal/day)
1400.1 ± 35.92 1060.0 ± 40.25* 1176.3 ± 25.05*+
Fasting glucose (mmol/l) 4.4 ± 0.07 3.9 ± 0.09* 4.2 ± 0.08+
Total cholesterol (mmol/l) 4.2 ± 0.14 4.6 ± 0.26 5.2 ± 0.27*+
HDL-cholesterol (mmol/l) 1.6 ± 0.08 1.5 ± 0.10 1.6 ± 0.08
LDL-cholesterol (mmol/l) 2.1 ± 0.09 2.4 ± 0.18 3.0 ± 0.21*+
Free fatty acids (mmol/l) 0.64 ± 0.06 0.16 ± 0.02* Not measured
Total serum protein (g/l) 79.1 ± 1.49 68.7 ± 2.01* 75.5 ± 1.04+
Albumin (g/l) 46.4 ± 1.22 43.8 ± 1.12 47.6 ± 0.72+
Total bone mineral density (g/
cm2)
1.09 ± 0.02 1.04 ± 0.02* Not measured
Lumbar (L1-L4) bone mineral 
density (g/cm2)
1.03 ± 0.03 0.86 ± 0.03* Not measured
Proximal femur bone mineral 
density (g/cm2)
0.98 ± 0.02 0.78 ± 0.04* Not measured
IGF-1 (ng/ml) NA 156 ± 18 NA
MIC-1 (pg/ml) 1051 ± 83 1872 ± 200* 1530 ± 169*+
Leptin (ng/ml) 11.8 ± 1.78 0.97 ± 0.23* 2.6 ± 0.66*+
Anthropometric, hormonal and biochemical characteristics of the control group of normal-weight healthy women and patients with anorexia 
nervosa both before (AN pre-treatment) and after (AN post-treatment) treatment. Values are means ± SEM. Statistical significance is from 
unpaired t-test or Mann-Whitney test (AN vs. controls) and from paired t-test or Wilcoxon Signed Rank Test (post- vs. pre-treatment values in 
AN) as appropriate. *p < 0.05 vs. controls; +p < 0.05 vs. pre-treatment values. NA - not availableDostálová et al. Nutrition & Metabolism 2010, 7:34
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IGF-1, lumbar bone mineral density, age, duration of ill-
ness and post-treatment glucose, total protein and albu-
min as independent variables. Similarly as in previous
cases none of the factors included was identified as statis-
tically significant independent predictor of pre-treatment
MIC-1 concentrations.
Finally, to assess a possible role of MIC-1 levels in the
regulation bone mineral density two multiple regression
analyses were performed. In the first one, pre-treatment
bone mineral density was set as dependent variable and
age, post-treatment MIC-1, post-treatment blood glu-
cose, post-treatment BMI, post-treatment IGF-1, post-
Figure 1 Serum concentrations of macrophage inhibitory cytokine-1 in anorexia nervosa. Serum concentrations of macrophage inhibitory cy-
tokine-1 (MIC-1; pg/ml) in normal-weight healthy control women (C; n = 25), patients with anorexia nervosa before the beginning of any treatment 
(AN pre-treatment; n = 16) and patients with anorexia nervosa after two months of refeeding (AN post-treatment; n = 16). *p < 0.05 vs. controls (Mann-
Whitney test), +p < 0.05 vs. pre-treatment values (Wilcoxon Signed Rank Test).
Table 2: Relationships of MIC-1 with other parameters in combined population.
AN + C
(n = 41)
BMI LBM Glucose Cholesterol Albumin BMD 
lumbar
Leptin REE age
MIC1 r -0.52 -0.59 -0.36 0.47 -0.49 -0.53 -0.43 -0.64 -0.57
p 0.000 0.001 0.02 0.002 0.008 0.003 0.04 0.000 0.000
Statistically significant relationships of pre-treatment concentrations of macrophage inhibitory cytokine-1 (MIC-1) with anthropometric, 
hormonal and biochemical parameters calculated in a combined population of normal-weight healthy women and untreated patients with 
anorexia nervosa (n = 41). Statistical significance is from Spearman Correlation Test. Correlations were controlled for body mass index (BMI). AN 
- anorexia nervosa, C - control group, LBM - lean body mass, BMD - bone mineral density, REE - resting energy expenditureDostálová et al. Nutrition & Metabolism 2010, 7:34
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treatment albumin and post-treatment Buzby nutritional
index as independent variables. In the second one, pre-
treatment bone mineral density was set as dependent
variable and age, pre-treatment MIC-1, pre-treatment
blood glucose, pre-treatment BMI, pre-treatment IGF-1,
pre-treatment albumin and pre-treatment Buzby nutri-
tional index as independent variables. None of the factors
included was identified as statistically significant inde-
pendent predictor of pre-treatment bone mineral density.
Discussion
The most important finding of the present study is that
chronically malnourished patients with AN have signifi-
cantly increased serum MIC-1 concentrations as com-
pared with healthy normal-weight women. Partial
realimentation improved their nutritional status and sig-
nificantly reduced serum MIC-1 concentrations in AN.
Furthermore, serum MIC-1 significantly inversely corre-
lated with Buzby nutritional risk index, serum insulin-like
growth factor-1, serum glucose, serum total protein,
serum albumin, and bone mineral density in women with
AN. Post-treatment serum MIC-1 concentrations signifi-
cantly positively correlated with the duration of AN.
The overexpression and elevated serum levels of MIC-1
have been previously documented in rheumatoid arthritis
and in numerous types of cancer [22-26]. Although
serum MIC-1 levels have been shown to predict the diag-
nosis and metastatic progression of various cancers
[22,25], its exact mode of action and major effects in
humans are still only partially understood. In fact, there is
only one study that clearly described a direct role of MIC-
1 as an inducer of cancer-related anorexia and weight loss
in mice [30]. Here we show for the first time that severely
malnourished patients with AN, similarly to cachectic
cancer patients, exhibit elevated serum MIC-1 levels.
However, the nature of our study does not allow us to
determine whether elevated MIC-1 levels play a role in
chronic metabolic complications of anorexia nervosa or
whether they are rather a consequence of chronic malnu-
trition of these patients.
Another important finding of our study is the fact that
elevated serum MIC-1 concentrations in patients with
AN were significantly reduced by partial realimentation;
albeit they still remained significantly higher than in
healthy women. Reduction of serum MIC-1 during reali-
mentation in AN may due to increased lean body mass
together with partial normalization of some of metabolic
parameters (total serum protein, albumin, glucose) dur-
ing realimentation. One can speculate that decreased
MIC-1 concentrations during nutritional treatment can
also be a part of useful adaptive mechanism to increase
the feeding drive in the state of refeeding after long-term
starvation [30]. Alternatively, changes of circulating MIC-
1 levels after partial realimentation may suggest that
MIC-1 is a marker of response to refeeding in anorexia
nervosa patients.
The duration of the illness significantly influences the
degree and severity of long-term nutritional, metabolic
and endocrine abnormalities in AN [33-36]. It was previ-
ously postulated, that in bulimic patients, circulating lep-
tin was inversely related with the duration of the illness
and the frequency of binging/vomiting [37]. However, to
our best knowledge, the biological markers of the chro-
nicity of AN are mostly unknown. Here we showed that
serum MIC-1 concentrations in patients with AN posi-
tively correlated with the duration of the illness and age.
Higher age of patients with anorexia nervosa commonly
suggests longer duration of illness increasing the likeli-
hood of chronic complications. Collectively, our results
suggest the possible relationship of MIC-1 concentrations
Table 3: Relationships of MIC-1 with other parameters in patients with anorexia nervosa.
AN
(n = 16)
NRI-2 IGF-1 GLU-2 TP-2 albumin-2 BMD
lumbar
duration of 
illness
age
Pre-
treatment 
MIC1
r -0.60 - 0.65 NS -0.65 -0.55 NS NS 0.53
p 0.01 0.02 0.007 0.03 0.03
Post-
treatment 
MIC1
r -0.68 - 0.60 -0.62 -0.52 -0.70 -0.55 0.53 0.51
p 0.004 0.04 0.01 0.04 0.002 0.03 0.03 0.04
Relationships of pre-treatment and post-treatment concentrations of macrophage inhibitory cytokine-1 (MIC-1) with anthropometric, hormonal 
and biochemical parameters calculated separately in a group of anorexia nervosa patients (n = 16). Statistical significance is from Spearman 
Correlation Test. Correlations were controlled for body mass index (BMI). AN - anorexia nervosa, C - control group, LBM - lean body mass, BMD - 
bone mineral density, NRI-2 - post-treatment nutritional risk index (Buzby), IGF-1, insulin-like growth factor, GLU-2 - post-treatment glucose, TP-
2, post-treatment total serum proteinDostálová et al. Nutrition & Metabolism 2010, 7:34
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with the duration of anorexia nervosa and possibly also
with its chronic course.
Osteopenia/osteoporosis is one of the most frequent
consequences of AN that is significantly influenced by
the duration of the disease [38]. Monitoring of decreased
bone mineral density in AN by DEXA can be used as an
effective screening tool and should be probably offered
routinely [39]. It is thus very important to identify predic-
tors of decreased BMD in AN to pinpoint the AN
patients with higher risk of osteoporosis that should
undergo DEXA examination. Previous studies postulated
that BMI [34], duration of the illness, presence of amen-
orrhea [40] and peptide YY [41] were strongly associated
with decreased BMD in patients with AN. Here we found
in univariate correlation analysis that post-treatment cir-
culating MIC-1 levels were inversely related to lumbar
BMD. In multiple regression analysis with BMD as inde-
pendent variable after inclusion of body mass index
among independent parameters relationship between
both pre- and post-treatment circulating MIC-1 levels
and lumbar BMD was not statistically significant any-
more arguing rather against direct independent role of
M I C - 1  i n  t h e  r e g u l a t i o n  o f  b o n e  m e t a b o l i s m  i n  A N
patients. It has to be noted that the negative results of
multiple regression analysis with respect to association of
BMD and circulating MIC-1 levels could have been also
affected by relatively low numbers of patients in our
study.
Our results are in agreement with proposed role of
MIC-1 in wasting syndrome such as cancer cachexia and
AN. In contrast to cancer cachexia where MIC-1 is pre-
dominantly produced by tumors, the origin of circulating
MIC-1 in patients with AN is unclear and should be fur-
ther investigated. MIC-1 is significantly increased under
inflammatory conditions [21] and is extensively produced
by macrophages [14] and also by adipocytes [15]. Taken
together, these findings suggest that adipose tissue may
be in general one of the sources of MIC-1. However, the
major contribution of fat to the production of MIC-1 in
anorectic patients appears questionable in the context of
decreased total fat mass in these patients. Moreover,
MIC-1 concentrations in AN decreased after partial
refeeding and weight gain when body fat content
increases and we failed to find any relationship between
body fat content and serum MIC-1 levels in our cohort of
patients. In addition, we have recently described
increased levels of circulating MIC-1 also in obese and
type 2 diabetic women [42]. The fact that circulating lev-
els of MIC-1 are increased in cachectic cancer and AN
patients as well as in patients with obesity despite oppo-
site changes in body weight and body fat content argues
rather against a direct role for body weight and body fat
content per se in the regulation of circulating MIC-1 lev-
els.
Previous studies indicated a possible involvement of
oxidative stress in the induction of MIC-1 synthesis in
humans [15]. The presence of increased oxidative stress
[43-45] could potentially explain why both malnourished
and obese patients display increased MIC-1 levels. We
suggest that both extreme cachexia in patients with can-
cer and AN and morbid obesity may result in nutritional
stress and subsequently oxidative stress in adipocytes and
other tissues which may in turn stimulate MIC-1 produc-
tion. The design and other limitations of our study do not
allow us to directly test this hypothesis. Nevertheless, we
have previously demonstrated that local changes in
mRNA expression of some of proinflammatory cytokines
in subcutaneous adipose tissue of malnourished patients
with AN share some similarities with changes in patients
with obesity suggesting that local inflammatory response
is present in adipose tissue of both cachectic and obese
patients [46,47]. Another possible site of MIC-1 produc-
tion may be the liver [48].
Conclusions
We demonstrated that AN is accompanied by signifi-
cantly elevated serum MIC-1 levels that are reduced by
partial realimentation. Clinical significance of these find-
ings and possible role of MIC-1 in the etiopathogenesis of
anorexia nervosa and its chronic complications needs to
be further clarified.
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